title: A 3-dimensional in vitro model of epithelioid granulomas induced by high aspect ratio nanomaterials.
abstract: BACKGROUND
  The most common causes of granulomatous inflammation are persistent pathogens and poorly-degradable irritating materials. A characteristic pathological reaction to intratracheal instillation, pharyngeal aspiration, or inhalation of carbon nanotubes is formation of epithelioid granulomas accompanied by interstitial fibrosis in the lungs. In the mesothelium, a similar response is induced by high aspect ratio nanomaterials, including asbestos fibers, following intraperitoneal injection. This asbestos-like behaviour of some engineered nanomaterials is a concern for their potential adverse health effects in the lungs and mesothelium. We hypothesize that high aspect ratio nanomaterials will induce epithelioid granulomas in nonadherent macrophages in 3D cultures.
  
  
  RESULTS
  Carbon black particles (Printex 90) and crocidolite asbestos fibers were used as well-characterized reference materials and compared with three commercial samples of multiwalled carbon nanotubes (MWCNTs). Doses were identified in 2D and 3D cultures in order to minimize acute toxicity and to reflect realistic occupational exposures in humans and in previous inhalation studies in rodents. Under serum-free conditions, exposure of nonadherent primary murine bone marrow-derived macrophages to 0.5 μg/ml (0.38 μg/cm2) of crocidolite asbestos fibers or MWCNTs, but not carbon black, induced macrophage differentiation into epithelioid cells and formation of stable aggregates with the characteristic morphology of granulomas. Formation of multinucleated giant cells was also induced by asbestos fibers or MWCNTs in this 3D in vitro model. After 7-14 days, macrophages exposed to high aspect ratio nanomaterials co-expressed proinflammatory (M1) as well as profibrotic (M2) phenotypic markers.
  
  
  CONCLUSIONS
  Induction of epithelioid granulomas appears to correlate with high aspect ratio and complex 3D structure of carbon nanotubes, not with their iron content or surface area. This model offers a time- and cost-effective platform to evaluate the potential of engineered high aspect ratio nanomaterials, including carbon nanotubes, nanofibers, nanorods and metallic nanowires, to induce granulomas following inhalation.
authors: Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
authors: Vanesa C
authors: VC
authors: Sanchez
authors: Paula
authors: P
authors: Weston
authors: Aihui
authors: A
authors: Yan
authors: Robert H
authors: RH
authors: Hurt
authors: Agnes B
authors: AB
authors: Kane
references: Toxicology. 2010 Mar 10;269(2-3):136-47
references: 19857541
references: Immunobiology. 1982 Apr;161(3-4):274-82
references: 7047374
references: J Biomed Mater Res. 2000 Mar 15;49(4):435-47
references: 10602077
references: Scand J Immunol. 1997 Jun;45(6):596-604
references: 9201298
references: Am J Physiol Lung Cell Mol Physiol. 2008 Oct;295(4):L552-65
references: 18658273
references: J Biol Chem. 2001 Dec 21;276(51):47950-7
references: 11602590
references: ACS Nano. 2009 Jun 23;3(6):1485-92
references: 19459622
references: Toxicol Sci. 2006 Jul;92(1):5-22
references: 16484287
references: Exp Lung Res. 1999 Jan-Feb;25(1):1-6
references: 10027075
references: Part Fibre Toxicol. 2005 Oct 06;2:8
references: 16209704
references: Arch Pathol Lab Med. 2010 May;134(5):667-90
references: 20441499
references: Part Fibre Toxicol. 2009 Dec 31;6:35
references: 20043844
references: Nat Nanotechnol. 2008 Jul;3(7):423-8
references: 18654567
references: Toxicol Sci. 2008 Jan;101(1):4-21
references: 17602205
references: Am J Pathol. 1989 Jun;134(6):1189-99
references: 2667373
references: Histol Histopathol. 2001 Apr;16(2):645-53
references: 11332720
references: Toxicol Sci. 2005 Dec;88(2):614-29
references: 16177241
references: Annu Rev Immunol. 2009;27:451-83
references: 19105661
references: Nanomedicine (Lond). 2006 Aug;1(2):229-34
references: 17716112
references: Histopathology. 2007 Feb;50(3):289-310
references: 17257125
references: Trends Immunol. 2004 Dec;25(12):677-86
references: 15530839
references: Br Med Bull. 2002;61:45-61
references: 11997298
references: Immunity. 2010 May 28;32(5):593-604
references: 20510870
references: Free Radic Biol Med. 2003 Aug 15;35(4):327-40
references: 12899936
references: J Biomed Mater Res. 2000 Jan;49(1):141-5
references: 10559757
references: Toxicol Appl Pharmacol. 2005 Sep 15;207(3):221-31
references: 16129115
references: J Pathol. 1997 May;182(1):99-105
references: 9227348
references: J Immunol. 1994 Jun 15;152(12):5883-9
references: 7911491
references: Toxicol Sci. 2009 Dec;112(2):273-5
references: 19783844
references: Cell Microbiol. 2004 May;6(5):423-33
references: 15056213
references: J Leukoc Biol. 2010 Jan;87(1):59-67
references: 20052800
references: Crit Rev Toxicol. 2009;39(8):629-58
references: 19743943
references: Part Fibre Toxicol. 2010 Mar 22;7:5
references: 20307263
references: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Sep-Oct;1(5):511-29
references: 20049814
references: J Clin Invest. 1998 Jul 15;102(2):445-54
references: 9664087
references: Am Rev Respir Dis. 1983 Oct;128(4):680-7
references: 6625345
references: Semin Respir Infect. 1998 Sep;13(3):221-8
references: 9764953
references: J Intern Med. 2010 Jan;267(1):89-105
references: 20059646
references: Nat Rev Immunol. 2004 Aug;4(8):583-94
references: 15286725
references: Inhal Toxicol. 2008 Jun;20(8):741-9
references: 18569096
references: Toxicol Sci. 2009 Dec;112(2):468-81
references: 19584127
references: Toxicol Sci. 2004 Jan;77(1):126-34
references: 14514958
references: Am J Pathol. 1987 Sep;128(3):426-45
references: 2820232